CRBP

2.06015.40%
AA

Anne Altmeyer

Independent Director

Dr. Anne Altmeyer, Ph. D., M. B. A, M. P. H. serves as CEO & Director of TigaTx, Inc. She served as Chief Business Officer at Sigilon Therapeutics, Inc. since 2019 until January 2021. She serves as President, Treasurer, Secretary, CEO & Director of TigaTx, Inc. She serves as an Independent Director at Corbus Pharmaceuticals Holdings, Inc. since September 20, 2022. She had been Chief Business Officer of Adicet Bio, Inc. since January 5, 2017. Since July 2024, Dr. Altmeyer is serving on the board of directors for Antennova Limited as an independent director. She joined Adicet from Baxalta where she served as Vice President of Negotiations, Global Business Development & Licensing. Prior to Baxalta, she more than a decade at Novartis in positions of increasing responsibility, as Vice President of Global Business Development and Licensing, Head of Negotiations of the Oncology Business Unit and Molecular Diagnostics. During her tenure at Novartis, she played a lead role in key transactions that expanded and strengthened the Novartis oncology portfolio. Before joining Novartis, She managed project teams in various therapeutic areas at Merck & Co and worked as its Project Manager. She holds a Ph. D. in molecular immunology from Strasbourg University, France and an M. P. H and M. B. A from the University of Medicine and Dentistry of New Jersey/Rutgers University respectively, USA. She performed a Postdoctoral Fellowship at New York University School of Medicine and subsequently became a Research Associate at Cornell University Medical College.

Positions